The bill directs the Secretary of Veterans Affairs to run a demonstration project testing whether FDA‑cleared over‑the‑counter (OTC) hearing aids can be covered under VA’s hearing-aid benefit and to evaluate the fiscal impact of doing so. The project must compare FDA‑cleared OTC devices against audiologist‑fitted prescription hearing aids, measure both clinical and self‑reported outcomes, and produce an interim and final report to Congress.
Separately, the bill requires the Comptroller General to study veterans’ access to hearing aids and related benefits, including need, coverage gaps, effectiveness of current coverage, and potential procurement approaches. Together the demonstration and GAO study are intended to give VA and Congress evidence to decide whether to add permanent coverage for FDA‑cleared OTC hearing aids under 38 U.S.C. 1707(b).
At a Glance
What It Does
Requires VA to start a demonstration (within one year of enactment) that compares FDA‑cleared OTC hearing aids to audiologist‑fitted prescription devices and to evaluate the fiscal impact of permanent OTC coverage. The demo must include study groups for each device type and measure clinical and patient‑reported outcomes over a two‑year period.
Who It Affects
Enrolled veterans with mild‑to‑moderate hearing loss who pass an audiologist clinical evaluation and have smartphone access; VA audiology clinics and facilities selected to run the demo; manufacturers of FDA‑cleared OTC hearing aids and VA procurement offices.
Why It Matters
This creates a defined pathway for evidence‑based consideration of OTC hearing aids within VA benefits—potentially expanding access while forcing VA to quantify short‑ and long‑term costs and clinical tradeoffs before changing entitlement rules.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill tasks VA with a controlled, two‑year demonstration to see whether FDA‑cleared OTC hearing aids can serve veterans as an alternative to prescription, audiologist‑fitted devices and at what cost. VA must design the project to produce head‑to‑head comparisons between the two approaches, collect both objective (speech‑in‑noise) and subjective (self‑reported benefit) outcomes, and explicitly evaluate the fiscal consequences of making OTC coverage permanent under the statutory hearing‑aid benefit.
Participation is limited to veterans enrolled in VA’s patient enrollment system who, after a clinical evaluation by an audiologist, are judged appropriate candidates for OTC devices (no FDA ‘red flag’ contraindications) and who can operate OTC features via a mobile device. VA must place the demo in at least two medical centers across different Veterans Integrated Services Networks chosen to capture urban and rural veteran populations.
The Secretary must allocate participants approximately equally between the OTC group and the audiologist‑fitted prescription group to support comparative analysis. Operationally, the demonstration requires VA to standardize how audiologists perform the clinical eligibility assessment, to collect baseline and follow‑up speech‑in‑noise tests and patient‑reported outcome measures, and to track costs over a two‑year follow‑up.
The statute also directs stakeholder consultation—VA must solicit input from consumer groups representing people with mild‑to‑moderate hearing loss while designing and concluding the project. Reporting deadlines are built into the statute: an interim report to Congress after one year of the demo and a final report within 180 days of its completion that must include VA’s fiscal analysis and recommendations.
Separately, the Comptroller General must deliver a study to Congress (due 18 months after enactment) on the national need for hearing aids among people with mild‑to‑moderate hearing loss, how coverage currently performs, and potential programmatic changes for VA benefits and procurement strategies.
The Five Things You Need to Know
The Secretary must begin the demonstration no later than one year after enactment and run it for two years.
Participant eligibility requires VA enrollment, an audiologist’s clinical determination that an FDA‑cleared OTC device is medically appropriate for mild‑to‑moderate loss and no FDA‑specified red flags, and access to a smartphone or successor technology to operate device features.
VA must run the demo at a minimum of two medical centers in different VISNs chosen to represent rural and urban veteran populations.
The study design must include two groups—FDA‑cleared OTC devices and audiologist‑fitted prescription hearing aids—with approximately equal participant allocation to each group.
VA must submit an interim report after one year and a final report within 180 days after the demo ends that evaluates fiscal impact; separately, the Comptroller General’s report is due 18 months after enactment and must examine need, coverage, effectiveness, and procurement options.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the act’s name: Veterans Hearing Aid Improvement Act of 2026. This is a formal label only and carries no programmatic effect, but it signals congressional intent to focus on hearing‑aid access for veterans.
Create demonstration project and set duration
Directs the VA Secretary to commence a demonstration project to test coverage of FDA‑cleared OTC hearing aids under 38 U.S.C. 1707(b) and requires VA to run the demonstration for two years. Practically, this converts a policy question—whether to add OTC devices to VA’s benefit—into an evidence project with a bounded timeframe to produce data for decision‑making.
Who can enroll and clinical screening requirements
Defines eligibility narrowly: veterans must be enrolled in VA’s patient enrollment system, pass an audiologist clinical evaluation showing OTC devices are medically appropriate for mild‑to‑moderate loss, have no FDA red‑flag conditions, and have access to a mobile device and connectivity. That mix of clinical gatekeeping and a technology access requirement limits the demo population to veterans likely to benefit from consumer‑grade, app‑enabled devices, which will affect generalizability.
Minimum site selection across VISNs
Requires VA to run the demo at not fewer than two VA medical facilities in different Veterans Integrated Services Networks, selected for their ability to reach diverse veteran populations in both rural and urban settings. This ensures geographic and demographic variation but leaves VA discretion on the precise sites and scale, which will shape the demo’s external validity.
Comparative groups, allocation, and metrics
Requires VA to include an FDA‑cleared OTC group and an audiologist‑fitted prescription group, with approximately equal participant allocation. VA must measure clinical outcomes (speech recognition in noise) and self‑reported benefit, and evaluate fiscal impacts over a two‑year follow‑up. Those choices push VA toward a comparative effectiveness framework, but the statute leaves important design details—randomization, blinding, sample size, and specific outcome instruments—to VA discretion.
Stakeholder input, congressionally required reports, and device definition
Requires consultation with consumer and stakeholder organizations during the demo and mandates both an interim report (one year after start) and a final report within 180 days after project completion; the final report must include an evaluation of the fiscal impact of permanently covering OTC devices. The statute defines 'FDA‑cleared, over‑the‑counter hearing aid' to mean devices cleared under the FDA and regulated under FDCA §520(q), and that offer personalization through software or apps, which narrows the universe of eligible devices to those meeting that regulatory pathway and technological profile.
Comptroller General study and recommendations
Directs the GAO to study the population with mild‑to‑moderate hearing loss, existing medical coverage and its effectiveness, and optionally to examine contract design for purchasing devices; GAO must report to Congress within 18 months. That independent study complements VA’s operational demo by offering a broader, system‑level assessment that can inform benefit structure and procurement strategy.
This bill is one of many.
Codify tracks hundreds of bills on Veterans across all five countries.
Explore Veterans in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Veterans with mild‑to‑moderate hearing loss who are enrolled in VA and technologically equipped—potential for faster access to lower‑cost, self‑managed devices if the demo supports permanent coverage.
- Rural veterans—because site selection requires inclusion of facilities serving rural populations, the demo tests whether OTC devices reduce travel and access barriers in areas with limited audiology services.
- Manufacturers of FDA‑cleared OTC hearing aids—clear evidence of VA interest and a statutory device definition tied to FDA 520(q) could create a new, institutional purchaser and procurement pathway.
- VA policymakers and budget analysts—will gain structured, comparative data on outcomes and costs to inform benefit design decisions rather than rely on external studies.
- Consumer advocacy organizations for people with hearing loss—statutory consultation and reporting requirements give these groups formal opportunities to influence design and highlight veteran experiences.
Who Bears the Cost
- VA (benefits budget and operating costs)—if permanent coverage is adopted, VA faces device procurement costs, service support, and potential increases in utilization; even the demo requires operational resources for staffing, IT, and data collection.
- VA audiology clinics and clinicians—must perform clinical eligibility assessments, collect outcome measures, and integrate new device workflows and training, adding to clinic workloads during and after the demo.
- Veterans without smartphones or reliable connectivity—effectively excluded from the demo and from OTC device pathways under the statute unless they acquire compatible technology, shifting access burdens onto some veterans.
- VA procurement offices and contracting partners—will need to develop purchasing approaches for FDA‑cleared OTC devices that may not fit existing device contract categories and to manage vendor competition and pricing.
- Private audiology practices and suppliers of prescription devices—could face competitive pressure if VA moves toward covering lower‑cost OTC options broadly, with downstream effects on market demand for premium, prescription‑fitted products.
Key Issues
The Core Tension
The bill’s central dilemma is expanding access and lowering costs through OTC hearing aids versus preserving clinical oversight and high‑quality individualized fitting: accelerating access may help many veterans quickly and cheaply, but it could also shift clinical responsibility, exacerbate disparities for veterans without digital access, and leave VA holding uncertain long‑term fiscal obligations if device performance and replacement patterns diverge from expectations.
The statute forces VA into a classic evidence‑building posture but leaves many implementation knobs unspecified. The requirement for an audiologist clinical assessment plus smartphone access narrows participants to veterans likely to do well with OTC devices, which improves internal validity but limits generalizability to veterans without connectivity or comorbidities.
VA must also decide on randomization, sample size, and the specific metrics and instruments to use for speech‑in‑noise and patient‑reported outcomes; those design choices will substantially affect the strength and credibility of whatever fiscal conclusions VA draws.
The fiscal analysis called for in the final report is conceptually straightforward—compare device and service costs against outcomes—but practically complicated. Short‑term device cost savings may be offset by follow‑up services, device replacement cycles, warranty and support, and heterogeneity in device performance across subgroups.
Procurement is another wildcard: defining eligible devices by FDA 520(q) clearance narrows suppliers but could limit competition if few vendors meet that regulatory standard, potentially raising prices. Finally, the smartphone requirement and reliance on app‑driven personalization creates equity risks; absent mitigation, the demo may undercount veterans for whom technology or digital literacy is a barrier, producing skewed conclusions about population‑level benefits and costs.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.